BioMarin Announces Close of the Alesta Therapeutics Acquisition

ALE1Positive

AI Analysis

Summary

BioMarin Pharmaceutical completed its acquisition of Alesta Therapeutics, adding ALE1, a potential first oral therapy for hypophosphatasia, to its clinical pipeline.

Outcome Details

BioMarin completed acquisition of Alesta Therapeutics

Importance:7/10

Sentiment:

0.60

M&Apipeline expansionoral therapyrare disease

Related Companies

$BMRN

Read the original article

Published by PR Newswire Biotech on September 1, 2026 1:05 PM

Read Original